Acutaas Chemicals Q1 FY27: Revenue Surges 59.1% to ₹329.7 Cr, Battery & Semiconductor Chemicals Drive Growth
Acutaas Chemicals reported a 59.1% YoY revenue increase to ₹329.7 crore in Q1 FY27. The company commenced commercial supply for its battery chemicals plant and expects strong growth from semiconductor chemicals. Advanced Pharmaceutical Intermediates revenue grew 76.5% YoY to ₹292.7 crore. EBITDA and PAT saw significant increases. Full-year revenue growth is projected at 25%.
The significant revenue growth, commencement of commercial supply for battery chemicals, and positive outlook for semiconductor chemicals indicate a substantial positive impact on the company's financial performance and market position.
The company reported strong year-on-year growth in revenue, profit, and margins, driven by key segments like battery chemicals and semiconductor chemicals, and also received positive certifications.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has reported a strong Q1 FY27 performance, with revenue soaring by 59.1% year-on-year to ₹329.7 crore. This growth was primarily fueled by robust demand in their CDMO and NCE products, and significant traction in specialty chemicals, particularly battery chemicals and semiconductor chemicals.
The company announced the successful completion of its battery chemicals plant trial run and has commenced commercial supply, anticipating a rapid ramp-up due to unprecedented demand. The semiconductor chemicals segment is also witnessing strong growth, driven by increasing AI adoption boosting CPU and memory chip demand.
Acutaas Chemicals achieved a revenue of ₹292.7 crore from its Advanced Pharmaceutical Intermediates segment, a 76.5% year-on-year increase. The Specialty Chemicals segment generated ₹37 crore, despite a 10.6% year-on-year decline, as the company strategically phases out commodity chemicals to focus on higher-margin products.
Financially, gross profit increased by 73% to ₹190.9 crore, with gross margins expanding by 466 basis points to 57.9%. EBITDA more than doubled to ₹113.1 crore, with EBITDA margins at 34.3%. Profit After Tax (PAT) grew by 70.4% to ₹74.9 crore, with PAT margins at 22.7%.
Capital expenditure for Q1 FY27 stood at ₹56 crore, with ₹15 crore allocated to the Indichem site and ₹41 crore to the ACL site, primarily for the battery chemicals project and a pilot plant. The company also received 'Great Place to Work' and 'Responsible Care' certifications.
The Indichem plant for semiconductor chemicals is progressing ahead of schedule, with capex expected to be completed by the end of the current quarter, and revenue generation anticipated from the next financial year. The company reiterated its full-year revenue growth guidance of 25% with stable margins.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.